Diagnosis and treatment of Barrett's oesophagus

British Medical Bulletin

Volumn 107, Issue 1, 2013, Pages 117-132

  Lim, Yean Cheant ^a   Fitzgerald, Rebecca C ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Barrett's associated dysplasia; Barrett's oesophagus; Biomarkers; Endoscopic therapy; Intestinal metaplasia; Screening; Surveillance

Indexed keywords

PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; ARTICLE; AUTOFLUORESCENCE; BARRETT ESOPHAGUS; CANCER STAGING; CHEMOPROPHYLAXIS; DISEASE COURSE; DISEASE SURVEILLANCE; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGUS CARCINOMA; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; HUMAN; LYMPH NODE METASTASIS; NARROW BAND IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK FACTOR; CANCER GROWTH; CANCER RISK; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; EARLY DIAGNOSIS; ENDOMUCOSAL RESECTION; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; HIGH RISK PATIENT; HISTOPATHOLOGY; INTRAMUCOSAL CARCINOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCREENING TEST;

EID: 84887915266     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldt025     Document Type: Article

References (85)

1. Eloubeidi MA, Mason AC, Desmond RA et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003;98: 1627-33.
2. Zagari RM, Fuccio L, Wallander MA et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57: 1354-9.
3. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129: 1825-31.
4. de Jonge PJ, van Blankenstein M, Looman CW et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59: 1030-6.
5. Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4: 566-72.
6. Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365: 1375-83.
7. Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103: 1049-57.
8. Gatenby PA, Ramus JR, Caygill CP et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol 2008;43: 524-30.
9. Harrison R, Perry I, HaddadinWet al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007;102: 1154-61.
10. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C&Mcriteria. Gastroenterology 2006;131: 1392-9.
11. Jung KW, Talley NJ, Romero Y et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011;106:1447-55; quiz 1456.
12. Shariff MK, Bird-Lieberman EL, O'Donovan M et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. Gastrointest Endosc 2012;75: 954-61.
13. Kadri SR, Lao-Sirieix P, O'Donovan M et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010;341:c4372.
14. Lao-Sirieix P, Boussioutas A, Kadri SR et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009;58: 1451-9.
15. Benaglia T, Sharples LD, Fitzgerald RC et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013;144:62-73 e6.
16. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103: 788-97.
17. Kerkhof M, van Dekken H, Steyerberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007;50: 920-7.
18. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 2006;59: 1029-38.
19. Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105: 1523-30.
20. Kaye PV, Haider SA, Ilyas M et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009;54: 699-712.
21. Skacel M, Petras RE, Rybicki LA et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002;97: 2508-13.
22. Fitzgerald R, Ragunath K, di Pietro M et al. British Society of Gastroenterology Guidelines: Diagnosis and Management of Barrett's oesophagus. Gut 2013. In press.
23. Conio M, Repici A, Cestari R et al. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol 2005;11: 6650-5.
24. Mino-Kenudson M, Brugge WR, Puricelli WP et al. Management of superficial Barrett's epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27 cases. Am J Surg Pathol 2005;29: 680-6.
25. Quante M, Bhagat G, Abrams JA et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012;21: 36-51.
26. Wang X, Ouyang H, Yamamoto Y et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011;145: 1023-35.
27. Nicholson AM, Graham TA, Simpson A et al. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 2012;61: 1380-9.
28. Oberg S, DeMeester TR, Peters JH et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999;117: 572-80.
29. Ho KY. From GERD to Barrett's esophagus: is the pattern in Asia mirroring that in the West? J Gastroenterol Hepatol 2011;26: 816-24.
30. Su Z, Gay LJ, Strange A et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012;44: 1131-6.
31. Chak A, Ochs-Balcom H, Falk G et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006;15: 1668-73.
32. Spechler SJ, Sharma P, Souza RF et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140: 1084-91.
33. Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in nondysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61: 970-6.
34. Sikkema M, Looman CW, Steyerberg EW et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol 2011;106: 1231-8.
35. Moayyedi P, Burch N, Akhtar-Danesh N et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008;27: 316-20.
36. Wani S, Falk GW, Post J et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011;141:1179-86, 1186 e1.
37. Bird-Lieberman EL, Dunn JM, Coleman HG et al. Population-based study reveals new riskstratification biomarker panel for Barrett's esophagus. Gastroenterology 2012;143:927-35 e3.
38. Kastelein F, Biermann K, Steyerberg EW et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2012. [Epub ahead of print].
39. Wilkinson SP, Biddlestone L, Gore S et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13: 1205-9.
40. El-Serag HB, Aguirre TV, Davis S et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99: 1877-83.
41. Hillman LC, Chiragakis L, Shadbolt B et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180: 387-91.
42. Kastelein F, Spaander MC, Steyerberg EW et al. Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus. Clin Gastroenterol Hepatol 2013;11: 382-8.
43. Rees JR, Lao-Sirieix P, Wong A et al. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010:CD004060.
44. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006;55:442.
45. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009;181: 161-9.
46. Vaughan TL, Dong LM, Blount PL et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6: 945-52.
47. Heath EI, Canto MI, Piantadosi S et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99: 545-57.
48. Gatenby PA, Ramus JR, Caygill CP et al. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur J Cancer Prev 2009;18: 381-4.
49. Kastelein F, Spaander MC, Biermann K et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141:2000-8; quiz e13-4.
50. Parrilla P, Martinez de Haro LF, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003;237: 291-8.
51. Chang EY, Morris CD, Seltman AK et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg 2007;246: 11-21.
52. Attwood SE, Lundell L, Hatlebakk JG et al. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008;12:1646-54; discussion 1654-5.
53. Grant KS, Demeester SR, Kreger V et al. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2013;146: 31-7.
54. Gladman L, Chapman W, Iqbal TH et al. Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol 2006;18: 271-6.
55. Fountoulakis A, Zafirellis KD, Dolan K et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004;91: 997-1003.
56. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol 2009;104: 1356-62.
57. Garside R, Pitt M, SomervilleMet al. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006;10:1-142, iii-iv.
58. Hirst NG, Gordon LG, Whiteman DC et al. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol 2011;26: 247-54.
59. Mandal A, Playford RJ, Wicks AC. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Aliment Pharmacol Ther 2003;17: 1319-24.
60. Inadomi JM, Somsouk M, Madanick RD et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009;136:2101-14 e1-6.
61. Kara MA, Peters FP, Rosmolen WD et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. Endoscopy 2005;37: 929-36.
62. Pech O, Gossner L, Manner H et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007;39: 588-93.
63. Curvers WL, Herrero LA, Wallace MB et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 2010;139: 1106-14.
64. Peters FP, Brakenhoff KP, CurversWL et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 2008;67: 604-9.
65. Manner H, May A, Pech O et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008;103: 2589-97.
66. Young PE, Gentry AB, Acosta RD et al. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 2010;8: 1037-41.
67. Fernandez-Sordo JO, Konda VJ, Chennat J et al. Is Endoscopic Ultrasound (EUS) necessary in the pre-therapeutic assessment of Barrett's esophagus with early neoplasia? J Gastrointest Oncol 2012;3: 314-21.
68. Ackroyd R, Kelty CJ, Brown NJ et al. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 2003;35: 496-501.
69. Ragunath K, Krasner N, Raman VS et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 2005;40: 750-8.
70. Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360: 2277-88.
71. Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011;141: 460-8.
72. May A, Gossner L, Pech O et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002;14: 1085-91.
73. Moss A, Bourke MJ, Hourigan LF et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010;105: 1276-83.
74. Chung A, Bourke MJ, Hourigan LF et al. Complete Barrett's excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy 2011;43: 1025-32.
75. Pouw RE, Seewald S, Gondrie JJ et al. Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010;59: 1169-77.
76. Dulai PS, Pohl H, Levenick JM et al. Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study. Gastrointest Endosc 2013;77: 534-41.
77. Pouw RE,Wirths K, Eisendrath P et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010;8: 23-9.
78. Herrero LA, van Vilsteren FG, Pouw RE et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. Gastrointest Endosc 2011;73: 682-90.
79. van Vilsteren FG, Pouw RE, Seewald S et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011;60: 765-73.
80. Shand A, Dallal H, Palmer K et al. Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut 2001;48: 580-1.
81. Van Laethem JL, Peny MO, Salmon I et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46: 574-7.
82. Yuan J, Hernandez JC, Ratuapli SK et al. Prevalence of buried Barrett's metaplasia in patients before and after radiofrequency ablation. Endoscopy 2012;44: 993-7.
83. Titi M, Overhiser A, Ulusarac O et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology 2012;143:564-6 e1.
84. Westerterp M, Koppert LB, Buskens CJ et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 2005;446: 497-504.
85. Leers JM, DeMeester SR, Oezcelik A et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011;253: 271-8.